Neurokinin B increased seminal vesicle weight, tissue height, and fructose secretion in rats in a dose-dependent manner through NK3 receptors.
Fully reversible effectsAll neurokinin B effects on seminal vesicles reversed completely within 12 days of stopping treatment
What the researchers found
Neurokinin B at three doses (1 μg, 1 ng, and 10 pg) administered intraperitoneally for 12 days increased seminal vesicle weight, epithelial height, and seminal fructose levels in a dose-dependent manner. Senktide (an NK3R agonist) produced similar effects. SB222200 (an NK3R antagonist) slightly decreased these parameters.
Light microscopy showed increased epithelial height and folding in all neurokinin B and senktide groups. Immunohistochemistry for NK3 receptor expression showed no change with treatment, suggesting the receptor is constitutively expressed.
Critically, all effects reversed when rats were kept for 12 days without treatment, indicating the changes are stimulatory and reversible rather than permanent.
Why it matters
Neurokinin B is known to stimulate reproductive hormones through GnRH (gonadotropin-releasing hormone). But its direct effects on reproductive organs like seminal vesicles were unknown. This study shows neurokinin B has a stimulatory effect on seminal vesicle growth and function, which could be relevant for understanding male fertility and potentially for fertility treatments.
The numbers in context
- 10 rats per group (6 groups)
- Treatment: 12 days intraperitoneal
- Reversal period: 12 days without treatment
- Neurokinin B doses: 1 μg, 1 ng, 10 pg
- Senktide (agonist): 1 μg
- SB222200 (antagonist): 1 μg
- Increased: seminal vesicle weight, epithelial height, seminal fructose
- NK3R expression: unchanged
- All effects reversed after treatment cessation
How the study worked
Adult male Sprague Dawley rats (n=10 per group) received 12 days of intraperitoneal injections: neurokinin B at 1 μg, 1 ng, or 10 pg; senktide (NK3R agonist) at 1 μg; or SB222200 (NK3R antagonist) at 1 μg. Half were sacrificed after treatment, half kept for 12 more days without treatment (reversal period). Seminal vesicles were analyzed by light microscopy, immunohistochemistry, and seminal fructose measurement.
Who was studied
Adult male Sprague Dawley rats (n=10 per group, 6 groups) receiving neurokinin B, agonist, or antagonist
What this study cannot tell us
This was tested in rats, not people. The intraperitoneal injection route delivers peptide systemically, which differs from natural neurokinin B release patterns. The dose range spans a million-fold (1 μg to 10 pg), making dose-response interpretation complex. The study measured structural and biochemical changes but not actual fertility or sperm quality. NK3R expression did not change, which limits mechanistic interpretation.
How to read the evidence
Rated preliminary: well-designed animal pharmacology study with mechanism confirmation, but entirely in rats with no human data.
When this study was published
Published in 2024. Contributes to the growing understanding of neurokinin B's role in reproductive physiology.
The bigger picture
Neurokinin B is known to regulate reproductive hormones through GnRH. This study shows it also has direct effects on reproductive organs, expanding understanding of its role in male fertility.
Questions still open
- Could neurokinin B pathway manipulation treat male infertility?
- Do these effects translate to humans?
Common questions
What is neurokinin B?
Could this lead to fertility treatments?
Read the original research
Neurokinin B Administration Induces Dose Dependent Proliferation of Seminal Vesicles in Adult Rats.
Current protein & peptide science, 25(4), 339-352
Citation
Ramzan, Muhammad Haris; Shah, Mohsin; Ramzan, Faiqah. (2024). Neurokinin B Administration Induces Dose Dependent Proliferation of Seminal Vesicles in Adult Rats.. Current protein & peptide science, 25(4), 339-352. https://doi.org/10.2174/0113892037264538231128072614